Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The 2023-2024 influenza season included sustained elevated activity from December 2023 to February 2024 and continued activity through May 2024. Influenza A(H1N1), A(H3N2), and B viruses circulated during the season. METHODS: During 1 September 2023 to 31 May 2024, a multistate sentinel surveillance network of 24 medical centers in 20 US states enrolled adults aged ≥18 years hospitalized with acute respiratory illness. Consistent with a test-negative design, cases tested positive for influenza viruses by molecular or antigen test, and controls tested negative for influenza viruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccine effectiveness (VE) against influenza-associated hospitalization was calculated as (1 - adjusted odds ratio for vaccination) × 100%. RESULTS: Among 7690 patients, including 1170 influenza cases (33% vaccinated) and 6520 controls, VE was 40% (95% confidence interval [CI], 31%-48%) with varying estimates by age: 18-49 years, 53% (95% CI, 34%-67%); 50-64 years, 47% (95% CI, 31%-60%); ≥ 65 years, 31% (95% CI, 16%-43%). Protection was similar among immunocompetent patients (40%; 95% CI, 30%-49%) and immunocompromised patients (32%; 95% CI, 7%-50%). VE was statistically significant against influenza B (67%; 95% CI, 35%-84%) and A(H1N1) (36%; 95% CI, 21%-48%) and crossed the null against A(H3N2) (19%; 95% CI, -8% to 39%). VE was higher for patients 14-60 days from vaccination (54%; 95% CI, 40%-65%) than >120 days (18%; 95% CI, -1% to 33%). CONCLUSIONS: During 2023-2024, influenza vaccination reduced the risk of influenza A(H1N1)- and influenza B-associated hospitalizations among adults; effectiveness was lower in patients vaccinated >120 days prior to illness onset compared with those vaccinated 14-60 days prior.
Authors: Nathaniel M Lewis, Elizabeth J Harker, Seana Cleary, Yuwei Zhu, Carlos G Grijalva, James D Chappell, Jillian P Rhoads, Adrienne Baughman, Jonathan D Casey, Paul W Blair, Ian D Jones, Cassandra A Johnson, Natasha B Halasa, Adam S Lauring, Emily T Martin, Manju Gaglani, Shekhar Ghamande, Cristie Columbus, Jay S Steingrub, Abhijit Duggal, Jamie R Felzer, Matthew E Prekker, Ithan D Peltan, Samuel M Brown, David N Hager, Michelle N Gong, Amira Mohamed, Matthew C Exline, Akram Khan, Samantha A N Ferguson, Jarrod Mosier, Nida Qadir, Steven Y Chang, Adit A Ginde, Anne Zepeski, Christopher Mallow, Estelle S Harris, Nicholas J Johnson, Kevin W Gibbs, Jennie H Kwon, Ivana A Vaughn, Mayur Ramesh, Basmah Safdar, Diya Surie, Fatimah S Dawood, Sascha Ellington, Wesley H Self
Institutions: Centers for Disease Control and Prevention, Vanderbilt University, Vanderbilt University Medical Center, University of Michigan, Michigan Medicine, Baylor College of Medicine, Baylor Scott & White Medical Center - Temple, Baylor Scott & White Health, Texas A&M University, Baystate Medical Center, Baystate Health, Cleveland Clinic, Emory University, Hennepin County Medical Center, University of Utah, Intermountain Medical Center, Johns Hopkins University, Johns Hopkins Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, The Ohio State University Wexner Medical Center, The Ohio State University, Oregon Health & Science University, Stanford Medicine, Stanford University, University of Arizona, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, University of Colorado Anschutz, University of Iowa, University of Miami, University of Washington, Wake Forest University Health Sciences, Wake Forest University, Washington University in St. Louis, Henry Ford Health, Henry Ford Hospital, Yale University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Keywords: influenza vaccine effectiveness, H1N1 influenza, H3N2, influenza B, influenza-associated hospitalizations, 2023-2024 influenza season, test-negative design, immunocompromised patients, age-specific vaccine effectiveness, vaccination timing, acute respiratory illness, sentinel surveillance network
Open Access status: green
OpenAlex ID: W4409249489
